Boehringer-Ingelheim, a dedicated corporate partner of the National Scleroderma Foundation, announced that the FIBRONEER™-ILD trial met its primary endpoint. FIBRONEER™-ILD was a double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nerandomilast (BI 1015550) over at least 52 weeks in patients with PPF.
Learn more about the results of this study by visiting Boehringer-Ingelheim’s website.
The National Scleroderma Foundation is committed to keeping our community up to date on the latest with clinical research affecting people living with scleroderma. To sign up to receive our new Clinical Trials Connection newsletter, dedicated specifically to clinical trial information, please click here.
Disclaimer: The National Scleroderma Foundation in no way endorses any drugs, treatments, clinical trials or studies referenced in this newsletter. Information is provided to keep the community informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with your healthcare provider team for proper evaluation and treatment.